![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/22/2886352/0/en/Achilles-Therapeutics-Announces-Research-Collaboration-with-Arcturus-Therapeutics-to-Explore-Second-Generation-Personalized-mRNA-Cancer-Vaccines.html
https://www.globenewswire.com/news-release/2024/05/17/2884500/0/en/Achilles-Therapeutics-Receives-Nasdaq-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement.html
https://www.globenewswire.com/news-release/2024/05/08/2877641/0/en/Achilles-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/04/04/2857610/0/en/Achilles-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/04/04/2857599/0/en/Achilles-Therapeutics-Provides-Interim-Phase-I-IIa-Update-on-Clonal-Neoantigen-Reactive-T-Cells-in-Advanced-NSCLC-and-Melanoma-Including-First-Patients-Dosed-with-Enhanced-Host-Con.html
https://www.globenewswire.com//news-release/2024/02/05/2823382/0/en/Achilles-Therapeutics-to-Present-at-the-10th-Annual-Immuno-Oncology-360-Conference.html
https://www.globenewswire.com//news-release/2023/12/18/2797667/0/en/Achilles-Therapeutics-Announces-Publication-of-Nature-Cancer-Comment-on-Strategy-for-Improved-Neoantigen-Immunogenicity-Prediction.html
https://www.globenewswire.com//news-release/2023/11/13/2779526/0/en/Achilles-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Highlights.html
https://www.globenewswire.com//news-release/2023/09/22/2748190/0/en/Achilles-Therapeutics-Receives-Nasdaq-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement.html
https://www.globenewswire.com/news-release/2023/08/04/2718851/0/en/Achilles-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html